Clive Dix has joined Crescendo Biologics as chairman and will work closely with Mike Romanos, chief scientific officer, to drive the development of the company and its proprietary antibody fragment technologies following recent seed round fundraising of £4.5m.
Dix has spent more than 20 years in the pharmaceutical and biotechnology business. He is chairman of the BioIndustry Association, the trade association for innovative enterprises in the UK's bioscience sector, and was previously co-founder and ceo of PowderMed, a vaccines development company acquired by Pfizer in November 2006. He was formerly senior vice president, r&d and a board member of PowderJect Pharmaceuticals until its acquisition by Chiron Vaccines in 2003.
Dix began his career in industry at Ciba-Geigy and then GlaxoWellcome, which he left as UK research director in 2001.